Repository logo
 
Publication

Impact of 13-valent pneumococcal conjugate vaccination introduction in children on pneumonia hospitalizations among adults aged 65 or more in Portugal

2018-07-06Conference object Restricted access
Simple item page
dc.contributor.authorKislaya, Irina
dc.contributor.authorRodrigues, Ana Paula
dc.contributor.authorSousa-Uva, Mafalda
dc.contributor.authorGómez, Verónica
dc.contributor.authorFroes, Filipe
dc.contributor.authorNunes, Baltazar
dc.date.accessioned2019-02-27T16:02:58Z
dc.date.available2020-07-01T00:30:13Z
dc.date.issued2018-07-06
dc.descriptionResumo publicado em: Revue d'Épidémiologie et de Santé Publique. 2018 Jul;66(Suppl. 5):S363-64. Disponível em: https://www.sciencedirect.com/science/article/pii/S0398762018310460pt_PT
dc.description.abstractThe incidence of pneumonia and pneumonia related hospitalizations still increasing in different European and American Countries. However, in western countries this increase is driven by secondary diagnoses, recurrent pneumonia episodes in elderly and among those with comorbidities. Given the high frequency of Streptococcus pneumoniae among all pneumonia, it is reasonable to expect that a wide use of pneumococcal vaccines would reduce the burden of pneumonia in the elderly due to a direct and indirect effect. In Portugal, pneumococcal vaccines are available since 1996: pneumococcal polysaccharide vaccine (PPSV23) in 1996; heptavalent conjugated pneumococcal vaccines (PCV7) in 2001; PCV10 in April 2009 and PCV13 in January 2010. PPSV23 and PCV13 are widely recommended for risk groups and elderly. PCV7 serotypes reduced from 31% in 1999–2003 to 11% in 2009–2011 in non-invasive pneumococcal pneumonia (PP), but no decreasing trend was observed for PCV13 and PPSV23 serotypes until 2011. Trends in pneumococcal pneumonia after PCV13 introduction are not known in Portugal. Thus, this study aims to assess population level impact of infant PCV13 introduction on burden of pneumonia among adults aged 65 or more in Portugal through comparison of trends in PP hospitalization rates before and after PCV13 introduction.pt_PT
dc.description.sponsorshipH2020 Grant Nº 634446pt_PT
dc.description.versionN/Apt_PT
dc.identifier.urihttp://hdl.handle.net/10400.18/5977
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.subject13-valent Conjugated Pneumococcal Vaccinept_PT
dc.subjectInterrupted Time Series Analysispt_PT
dc.subjectHospitalizationpt_PT
dc.subjectOlder Adultspt_PT
dc.subjectPneumococcal Pneumoniapt_PT
dc.subjectDeterminantes da Saúde e da Doençapt_PT
dc.subjectEstados de Saúde e de Doençapt_PT
dc.titleImpact of 13-valent pneumococcal conjugate vaccination introduction in children on pneumonia hospitalizations among adults aged 65 or more in Portugalpt_PT
dc.typeconference object
dspace.entity.typePublication
oaire.citation.conferencePlaceLyon, Françapt_PT
oaire.citation.titleEuropean Congress of Epidemiology: Crises, epidemiological transitions and the role of epidemiologists, 4-6 July 2018pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typeconferenceObjectpt_PT

Files

Original bundle
Now showing 1 - 2 of 2
No Thumbnail Available
Name:
Poster_IMOVE+_Kislaya.pdf
Size:
1.02 MB
Format:
Adobe Portable Document Format
Download
No Thumbnail Available
Name:
Abstract.pdf
Size:
62.48 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

DEP - Posters/abstracts em congressos internacionais